Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Open access

Published version of a preprint

Abstract

Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti–PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair–deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti–PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. Significance: A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188–201. ©2016 AACR. See related commentary by Marabelle et al., p. 128. This article is highlighted in the In This Issue feature, p. 115

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-1223

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 1,337

Metadata

Authors
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., Palaskas, N., Rodriguez, G. A., Parisi, G., Azhdam, A., Chmielowski, B., Cherry, G., Seja, E., Berent-Maoz, B., Shintaku, I. P., Le, D. T., Pardoll, D. M., Diaz, L. A., Tumeh, P. C., Graeber, T. G., Lo, R. S., Comin-Anduix, B., & Ribas, A.
Affiliations
  • University of California, Los Angeles (US)
  • 1University of California, Los Angeles (UCLA), Los Angeles, California.
  • Johns Hopkins University (US)
Corresponding author
Ribas, Antoni
Venue
Cancer Discovery
Published
2017-02-01
Volume
7
Issue
2
Pages
188-201
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2557336488
Cited by
1,337
References
49
Citations by year
2026: 110 · 2025: 123 · 2024: 101 · 2023: 152 · 2022: 153 · 2021: 182 · 2020: 160 · 2019: 129 · 2018: 133 · 2017: 91
FWCI
63.65
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR000124, 5t32ar058921-04, UL1TR001881)
  • National Cancer Institute (P01CA168585, R01CA199205, T32CA009297, T32CA009120, R35CA197633)
  • National Institute of General Medical Sciences (T32GM008042)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR058921)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
anti-PD-1 therapy, primary resistance, loss-of-function mutations, melanoma, PD-L1 expression, interferon-gamma signaling, interferon-stimulated genes, immune checkpoint inhibitors, tumor mutational burden
MeSH terms
Colonic Neoplasms, Humans, Interferon-gamma, Melanoma, Mutation, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Line, Tumor, Janus Kinase 1, Janus Kinase 2, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. https://app.cochat.ai/papers/10.1158/2159-8290.cd-16-1223
The paper
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., Palaskas, N., Rodriguez, G. A., Parisi, G., Azhdam, A., Chmielowski, B., Cherry, G., Seja, E., Berent-Maoz, B., Shintaku, I. P., . . . Ribas, A. (2017). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-16-1223

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.